Literature DB >> 18481450

Basic concept of development and practical application of animal models for human diseases.

T Nomura1, N Tamaoki, A Takakura, H Suemizu.   

Abstract

The "humanized mouse" is a mouse harboring functioning human tissues used as in vivo human models for both physiological and pathological conditions. The NOD/Shi-scid IL2rgamma(null) (NOG) mouse, an excellent immunodeficient mouse used as the basis for the humanized mouse, requires strict genetic and environmental control for production and use in experiments. Genetic control using marker-assisted selection is described. In addition, NOG mice are easily affected by microbiological and proximate environmental factors, which can cause severe damage to the mice in some cases. Therefore, rigorous microbiological and environmental controls are necessary to ensure reproducibility of experimental results. At the end of this chapter, future aspects of the application of "humanized mice" based on novel super-immunodeficient mice such as NOG mice and Rag2(null) IL2rgamma(null) mice in biomedical research and testing are briefly reviewed.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18481450     DOI: 10.1007/978-3-540-75647-7_1

Source DB:  PubMed          Journal:  Curr Top Microbiol Immunol        ISSN: 0070-217X            Impact factor:   4.291


  9 in total

Review 1.  A paradigm shift: Cancer therapy with peptide-based B-cell epitopes and peptide immunotherapeutics targeting multiple solid tumor types: Emerging concepts and validation of combination immunotherapy.

Authors:  Pravin T P Kaumaya
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

2.  Patient-derived cancer modeling for precision medicine in colorectal cancer: beyond the cancer cell line.

Authors:  Dae Hee Pyo; Hye Kyung Hong; Woo Yong Lee; Yong Beom Cho
Journal:  Cancer Biol Ther       Date:  2020-03-25       Impact factor: 4.742

3.  A novel immunocompetent murine tumor model for the evaluation of RCAd-enhanced RDAd transduction efficacy.

Authors:  Huiping Wang; Fang Wei; Jufeng Zhang; Feng Wang; Huiming Li; Xiafang Chen; Kuangcheng Xie; Yufei Wang; Chuanyuan Li; Qian Huang
Journal:  Tumour Biol       Date:  2012-05-25

4.  Preclinical evaluation of KIT/PDGFRA and mTOR inhibitors in gastrointestinal stromal tumors using small animal FDG PET.

Authors:  Maria Abbondanza Pantaleo; Giordano Nicoletti; Cristina Nanni; Chiara Gnocchi; Lorena Landuzzi; Carmelo Quarta; Stefano Boschi; Margherita Nannini; Monica Di Battista; Paolo Castellucci; Stefano Fanti; Pier Luigi Lollini; Elena Bellan; Mauro Castelli; Domenico Rubello; Guido Biasco
Journal:  J Exp Clin Cancer Res       Date:  2010-12-30

5.  Livestock and Risk Group 4 Pathogens: Researching Zoonotic Threats to Public Health and Agriculture in Maximum Containment.

Authors:  Charles E Lewis; Bradley Pickering
Journal:  ILAR J       Date:  2022-01-07

6.  Lamin A and the LINC complex act as potential tumor suppressors in Ewing Sarcoma.

Authors:  Francesca Chiarini; Francesca Paganelli; Tommaso Balestra; Cristina Capanni; Antonietta Fazio; Maria Cristina Manara; Lorena Landuzzi; Stefania Petrini; Camilla Evangelisti; Pier-Luigi Lollini; Alberto M Martelli; Giovanna Lattanzi; Katia Scotlandi
Journal:  Cell Death Dis       Date:  2022-04-14       Impact factor: 9.685

7.  Murine Models of Chronic Viral Infections and Associated Cancers.

Authors:  D V Avdoshina; A S Kondrashova; M G Belikova; E O Bayurova
Journal:  Mol Biol       Date:  2022-10-05       Impact factor: 1.540

8.  Human responses against HER-2-positive cancer cells in human immune system-engrafted mice.

Authors:  C De Giovanni; G Nicoletti; L Landuzzi; F Romani; S Croci; A Palladini; A Murgo; A Antognoli; M L Ianzano; V Stivani; V Grosso; M Iezzi; L Stramucci; E Barbieri; R M Lemoli; P Nanni; P-L Lollini
Journal:  Br J Cancer       Date:  2012-08-28       Impact factor: 7.640

Review 9.  Patient-Derived Orthotopic Xenograft Models of Pediatric Brain Tumors: In a Mature Phase or Still in Its Infancy?

Authors:  Eva Hermans; Esther Hulleman
Journal:  Front Oncol       Date:  2020-01-08       Impact factor: 6.244

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.